Evidence map›Paper›PMID 37828456›Full record

ArticleBMC cancer2023

Plasma hepatocyte growth factor as a noninvasive biomarker in small cell lung cancer.

Cong Zhao, Li Tong, Bin Liu, Fei Qi, Zhiyun Zhang, Yi Guo, Yanxia Liu, Ying Wang, Lina Zhang, Baohua Lu and 2 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC cancer, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.0field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 5 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 1 country.

Cong Zhao *General Department, Beijing Chest Hospital, Capital Medical University, Beijing, 101149, China.
Li Tong *Department of Oncology, Beijing Chest Hospital, Capital Medical University, Beijing, China.
Bin Liu *Cancer research center, Tuberculosis and Thoracic Tumor Research Institute, Beijing Chest Hospital, Beijing, China.
Fei Qi *General Department, Beijing Chest Hospital, Capital Medical University, Beijing, 101149, China.
Zhiyun ZhangGeneral Department, Beijing Chest Hospital, Capital Medical University, Beijing, 101149, China.
Yi GuoEmergency Department, Dongfang Hospital Beijing University of Chinese Medicine, Beijing, China.
Yanxia LiuGeneral Department, Beijing Chest Hospital, Capital Medical University, Beijing, 101149, China.
Ying WangGeneral Department, Beijing Chest Hospital, Capital Medical University, Beijing, 101149, China.
Lina ZhangCancer research center, Tuberculosis and Thoracic Tumor Research Institute, Beijing Chest Hospital, Beijing, China.
Baohua LuGeneral Department, Beijing Chest Hospital, Capital Medical University, Beijing, 101149, China.
Baolan LiGeneral Department, Beijing Chest Hospital, Capital Medical University, Beijing, 101149, China.
Tongmei ZhangGeneral Department, Beijing Chest Hospital, Capital Medical University, Beijing, 101149, China. tongmeibj@163.com.
Beijing Chest Hospital · CNCapital Medical University · CNBeijing University of Chinese Medicine · CN

Funding

Beijing Municipal Administration of Hospitals Incubating Program PX2017050 to LZBeijing Municipal Science and Technology Commission Z171100001017038Tongzhou District Science and Technology Committee Project KJ2020CX010 to TZTongzhou Lianggao Talents Project YH201920
6 · The paper itself

Abstract

backgroundHepatocyte growth factor (HGF) is a peptide-containing multifunctional cytokine, which is overexpressed and/or activated in multiple malignancies and is reported to be associated with tumor development and inferior survival. At present, the role of HGF in small cell lung cancer (SCLC) has not been fully explored yet. MATERIALS AND

methodsThe expression of HGF and its value in predicting survival in SCLC were explored from GEO database and in pan-cancer analysis. Furthermore, we detected the expression of HGF using tumor tissue and paired plasma samples from a validation cohort of 71 SCLC patients at our institute. Correlation between tumor and plasma HGF expression and the prognostic values were analyzed.

resultsGEO database analysis revealed that tumor tissue had lower HGF expression than paired normal tissue in SCLC. At our institute, immunohistochemical staining showed negative expression of HGF in tumor tissue of SCLC at our institute (47/47, 100%). The average baseline plasma HGF was 1.28 (range,0.42-4.35) ng/ml. However, plasma HGF was higher in SCLC patients with patients with N

conclusionOur results revealed that plasma HGF rather than tumor HGF exhibited a potential role in predicting metastasis and survival in SCLC. Plasma HGF might be used as a non-invasive detecting and monitoring tool for SCLC.

Indexed as

Lung NeoplasmsSmall Cell Lung CarcinomaBiomarkersHepatocyte Growth FactorHumansPrognosisSignal TransductionBiomarkersHepatocyte Growth FactorHepatocyte growth factorMetastasesPan-cancer analysisPlasmaSmall cell lung cancer

Identifiers

PMID37828456
PMCPMC10568809
OpenAlexW4387578157

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.